Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.61 |
| ▸ | JAK3 | P52333 | 9/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 2/20 | 0.52 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.51 |
| ▸ | STAT6 | P42226 | 2/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853691 | 0.91 | JAK2 (0.75) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL2860948 | 0.88 | JAK2 (0.66) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL16478873 | 0.88 | JAK2 (0.68) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL2879211 | 0.88 | JAK2 (0.66) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL13253912 | 0.85 | JAK2 (0.82) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL13253275 | 0.85 | JAK2 (0.81) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL13253910 | 0.84 | JAK2 (0.62) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL13253186 | 0.83 | JAK2 (0.81) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL2859057 | 0.80 | JAK2 (0.63) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL30053325 | 0.80 | JAK2 (0.63) | JAK2JAK3HDAC1HDAC6JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885HDAC1 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.